COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms
Executive Summary
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.
You may also be interested in...
COVID-19 Pandemic Means Another Delay For Canadian Pricing Reforms
Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.
Pricing Reforms Prompt Canadian Business Rethink
The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.
Canada’s Drug Pricing Reform Faces Legal Challenge
Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.